Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Vaccinations01:51

Vaccinations

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the virus-host interface for the development of therapeutics against filoviruses.

Current opinion in virology·2026
Same author

Characterization of conserved residues in the mammarenavirus matrix protein Z using novel Lassa virus life cycle modelling assays.

Scientific reports·2026
Same author

Molecular characterization of arenavirus defective viral genomes reveals sequence features associated with their formation.

Journal of virology·2025
Same author

Application of a comprehensive approach to pathogen screening in a stowaway rat on an airplane.

Scientific reports·2025
Same author

Antiviral defense against filovirus infections: targets and evasion mechanisms.

Future microbiology·2025
Same author

Novel filoviruses: indication of a global threat or cause to reassess our risk perception?

Npj viruses·2025
Same journal

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Current ebola vaccines.

Thomas Hoenen1, Allison Groseth, Heinz Feldmann

  • 1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Intramural Research, Rocky Mountain Laboratories, Disease Modelling and Transmission Unit - Laboratory of Virology , 2A120A, 903 S 4th St, Hamilton, MT, USA. thomas.hoenen@nih.gov

Expert Opinion on Biological Therapy
|May 8, 2012
PubMed
Summary
This summary is machine-generated.

Ebola virus vaccines show promise, with several candidates highly protective in non-human primates. Further research is needed to establish safety and efficacy for human trials, but an effective ebolavirus vaccine is scientifically achievable.

More Related Videos

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Related Experiment Videos

Last Updated: May 22, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Ebolaviruses cause severe hemorrhagic fever with high fatality rates (up to 90%) in humans and non-human primates (NHPs).
  • No licensed human vaccines or specific treatments are currently available for ebolavirus infections.
  • Significant progress has been made in developing promising vaccine candidates, demonstrating high protection in NHPs.

Purpose of the Study:

  • To review potential scenarios for ebolavirus vaccine deployment.
  • To outline the requirements for effective ebolavirus vaccines.
  • To describe current vaccine platforms and their characteristics.

Main Methods:

  • Review of current ebolavirus vaccine candidates, including recombinant adenoviruses, vesicular stomatitis viruses (VSVs), human parainfluenza viruses, and virus-like particles.
  • Analysis of vaccine requirements for various deployment scenarios.
  • Evaluation of post-exposure protection demonstrated by specific vaccine platforms.

Main Results:

  • Several vaccine platforms, including recombinant VSVs, have shown high efficacy in NHPs.
  • Recombinant VSV-based vaccines have demonstrated potential for post-exposure protection.
  • Current vaccine candidates represent diverse technological approaches to ebolavirus prevention.

Conclusions:

  • Moving ebolavirus vaccine candidates into human trials and licensure is the critical next step.
  • Establishing mechanisms and correlates of protection is essential for vaccine approval.
  • Demonstrating safety, especially in immunocompromised populations, is a key requirement for licensure.